Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human)

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human)
Generic name
VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)
Manufacturer
Octapharma USA Inc
Product type
PLASMA DERIVATIVE
SPL set ID
a8ef06b8-b041-054e-e58d-fd8a994a8071
SPL ID
8b1223a8-df18-b5db-d5f5-6cc4889df0d4
Version
26
Effective date
2026-06-25
Source export date
2026-11-13
Source partition
1
Source file
https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/4245fd4310917b72c4a58c789d30a0b365e492ef46f48e107e3c3e16139b0499/drug-label-0001-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:21:49
Harmonized routes table
Harmonized routes
INTRAVENOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Anaphylaxis and severe hypersensitivity reactions are possible ( 5.1 ). Thromboembolic events may occur. Monitor plasma levels of FVIII activity ( 5.2 ) Neutralizing antibodies (inhibitors) to VWF and Factor VIII have occurred following administration of WILATE. Test for neutralizing antibodies if plasma VWF and/or Factor VIII level fail to increase as expected or if bleeding is not controlled after WILATE administration, ( 5.3 , 12.6 ). WILATE is made from human plasma and carries the risk of transmitting infectious agents ( 5.4 ). 5.1 Hypersensitivity Reactions Hypersensitivity reactions may occur with WILATE. Signs and symptoms include angioedema, burning and stinging at the infusion site, chills, flushing, generalized urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, and wheezing that may progress to severe anaphylaxis (including shock) with or without fever. Closely monitor patients receiving WILATE and observe for any symptoms throughout the infusion period. Because inhibitor antibodies may occur concomitantly with anaphylactic reactions, evaluate patients experiencing an anaphylactic reaction for the presence of inhibitors. [see Warnings and Precautions ( 5.3 )] 5.2 Thromboembolic Events In VWD, continued treatment using a FVIII-containing VWF product may cause an excessive rise in FVIII activity, which may increase the risk of thromboembolic events. Monitor plasma levels of VWF:RCo and FVIII activities in patients receiving WILATE to avoid sustained excessive VWF and FVIII activity levels. 5.3 Neutralizing Antibodies VWD Neutralizing antibodies (inhibitors) to VWF and Factor VIII have occurred following administration of WILATE [see Immunogenicity ( 12.6 )] . Monitor all patients for VWF and Factor VIII inhibitor development using appropriate clinical observations and laboratory tests. If the patient's plasma VWF and Factor VIII levels do not increase as expected, or if bleeding remains uncontrolled after WILATE administration, suspect the presence of an inhibitor (neutralizing antibodies) and perform appropriate testing. In patients with antibodies against VWF, VWF is not effective and WILATE administration may lead to severe adverse reactions. Consider other therapeutic options for such patients. Hemophilia A Monitor plasma Factor VIII activity by performing a validated test (e.g., one stage clotting assay), to confirm that adequate Factor VIII levels have been achieved and maintained [see Dosage and Administration ( 2.1 )] . Monitor for the development of Factor VIII inhibitors. Perform a Bethesda inhibitor assay if expected Factor VIII plasma levels are not attained, or if bleeding is not controlled with the expected dose of WILATE. Use Bethesda Units (BU) to report inhibitor levels. 5.4 Transmissible Infectious Agents WILATE is made from human plasma. Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent. There is also the possibility that unknown infectious agents may be present in the product. The risk that WILATE will transmit viruses has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and removing certain viruses during manufacture. Despite these measures, it may still potentially transmit disease. Record the batch number of the product every time WILATE is administered to a patient, and consider appropriate vaccination (against hepatitis A and B virus) of patients in regular/repeated receipt of WILATE. ALL infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Octapharma USA, Inc., at 1-866-766-4860. 5.5 Monitoring and Laboratory Tests Monitor plasma levels of VWF:RCo and FVIII activities in patients receiving WILATE to avoid sustained excessive VWF and FVIII activity levels, which may increase the risk of thromboembolism, particularly in patients with known clinical or laboratory risk factors. Monitor for development of VWF and FVIII inhibitors. Perform assays to determine whether VWF and/or FVIII inhibitor(s) is present if bleeding is not controlled with the expected dose of WILATE.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions (≥ 1%) in clinical trials on VWD were hypersensitivity reactions, urticaria, chest discomfort, and dizziness ( 6.1 ). The most common adverse reaction (≥ 1%) in clinical trials in hemophilia A was pyrexia (fever) ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Octapharma USA Inc. at 1-866-766-4860 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of WILATE cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 208 patients treated for VWD (28 patients aged <6 years, 16 patients aged 6 to <12 years, 22 patients aged 12 to <17 years and 142 adult patients) received 12144 WILATE infusions, including clinical studies that involved prophylactic use, treatment on demand, surgery, and pharmacokinetics. Of the 208 patients, 37 (17.8%) had VWD type 1, 51 (24.5%) had VWD type 2, and 110 (52.9%) had VWD type 3, and 10 (4.8%) had an unknown status; 115 (55.3%) patients were female and 93 (44.7%) patients were male. Overall, patients received 20,163,140 IU of WILATE during 11661 exposure days. The most common adverse drug reactions were hypersensitivity reactions (4 patients; 2%), dizziness (3 patients; 1.5%), urticaria and chest discomfort (each with 2 patients; 1%). A total of 136 hemophilia A previously treated patients (aged 11 to 66 years) received WILATE in 5 clinical studies that involved prophylactic use, treatment on demand, surgery and/or pharmacokinetics. All patients were male. Overall, patients received 19,317,004 IU of WILATE during 9001 exposure days. The most common adverse reaction was pyrexia (2 patients; 1.5%). Other adverse reactions included pruritus, headache and sleeping disorder (1 subject; 0.75%). Two out of 55 patients (3.6%) in the pivotal study of routine prophylaxis in severe hemophilia A had unexplained transient worsening of pre-existing thrombocytosis while on the study. 6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. The following adverse reactions have been identified during postmarketing use of WILATE:. Respiratory, thoracic, and mediastinal disorders: Dyspnea and cough Vasculardisorders: Hypertension Cardiac Disorders: Chest discomfort Gastrointestinal disorders: Abdominal pain Musculoskeletal and connective tissue disorders: Back pain Blood and Lymphatic System Disorders: Factor VIII inhibition and Von Willebrand factor inhibition Immune System Disorders: Hypersensitivity reactions and anaphylactic reactions

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.